These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 10688243)
1. Applied pharmacoeconomics: modeling data from internal and external sources. Sanchez LA; Lee JT Am J Health Syst Pharm; 2000 Jan; 57(2):146-55; quiz 155-6. PubMed ID: 10688243 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Moore S; Tumeh J; Wojtanowski S; Flowers C Value Health; 2007; 10(1):23-31. PubMed ID: 17261113 [TBL] [Abstract][Full Text] [Related]
3. Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting. Schwartzberg L Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):825-34. PubMed ID: 25227565 [TBL] [Abstract][Full Text] [Related]
4. Antiemetic overuse in patients receiving chemotherapy. Das M Lancet Oncol; 2016 Oct; 17(10):e428. PubMed ID: 27667572 [No Abstract] [Full Text] [Related]
5. Incorporation of uncertainty in health economic modelling studies. O'Hagan A; McCabe C; Akehurst R; Brennan A; Briggs A; Claxton K; Fenwick E; Fryback D; Sculpher M; Spiegelhalter D; Willan A Pharmacoeconomics; 2005; 23(6):529-36. PubMed ID: 15960550 [TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomics and formulary decision making. Sanchez LA Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy. Kwong WJ; Parasuraman TV Pharm Pract Manag Q; 1999 Apr; 19(1):28-41. PubMed ID: 10351607 [TBL] [Abstract][Full Text] [Related]
9. An introduction to Markov modelling for economic evaluation. Briggs A; Sculpher M Pharmacoeconomics; 1998 Apr; 13(4):397-409. PubMed ID: 10178664 [TBL] [Abstract][Full Text] [Related]
10. Impact of ondansetron and granisetron on chemotherapy-induced emesis in adults: the need for comparative pharmacoeconomic data. Hedayati S; Moatti JP; Seitz JF Clin Ther; 1994; 16(3):569-80. PubMed ID: 7923321 [TBL] [Abstract][Full Text] [Related]
11. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY Value Health; 2014; 17(1):5-14. PubMed ID: 24438712 [TBL] [Abstract][Full Text] [Related]
13. Use of pharmacoeconomics in prescribing research. Part 5: modelling--beyond clinical trials. Lang DL; Lopert R; Hill SR J Clin Pharm Ther; 2003 Oct; 28(5):433-9. PubMed ID: 14632969 [TBL] [Abstract][Full Text] [Related]
14. Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview. Dasbach EJ; Elbasha EH Pharmacoeconomics; 2017 Jul; 35(7):673-683. PubMed ID: 28456972 [TBL] [Abstract][Full Text] [Related]
15. Discrete event simulation: the preferred technique for health economic evaluations? Caro JJ; Möller J; Getsios D Value Health; 2010 Dec; 13(8):1056-60. PubMed ID: 20825626 [TBL] [Abstract][Full Text] [Related]
16. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. Stewart DJ; Dahrouge S; Coyle D; Evans WK J Clin Oncol; 1999 Jan; 17(1):344-51. PubMed ID: 10458253 [TBL] [Abstract][Full Text] [Related]
17. [Decision analytic modeling and their impact on health care decision making]. Inotai A; Kaló Z; Mészáros A Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636 [TBL] [Abstract][Full Text] [Related]
18. Using pharmacoeconomics to value pharmacotherapy. Hay JW Clin Pharmacol Ther; 2008 Aug; 84(2):197-200. PubMed ID: 18679182 [TBL] [Abstract][Full Text] [Related]